

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability under the Companies Ordinance)

(Stock Code: 00656)

ANNOUNCEMENT EXPECTED PROFIT GROWTH IN 2010 INTERIM RESULTS OF FOSUN PHARMA

Reference is made to the overseas regulatory announcement dated 29 July 2010 (the “**Announcement**”) and issued by Fosun International Limited (the “**Company**”) in relation to the expected profit growth in the 2010 interim results of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“**Fosun Pharma**”), a subsidiary of the Company and whose A shares are listed and traded on the Shanghai Stock Exchange (Stock Code: 600196).

The board of the directors of the Company would like to draw the attention of its shareholders and the investment public to the following information as set out in the Announcement:

I. Estimated Results of Fosun Pharma

1. Period of estimated results: 1 January 2010 to 30 June 2010.
2. Estimated results: In accordance with the estimation by Fosun Pharma, it is expected that the net profit attributable to shareholders of the listed company for the six months ended 30 June 2010 will increase by more than 50%, as compared to the same period of 2009. Details of the financial information will be disclosed in the 2010 interim report of Fosun Pharma.
3. The above estimated results have not been audited.

II. 2009 Interim Results of Fosun Pharma

1. Net profit attributable to the parent: RMB343,035,366.79
2. Earnings per share: RMB0.28

III. Reasons for the Expected Profit Growth of Fosun Pharma

The expected profit growth is primarily due to the profit increase contributed by the subsidiaries in, among others, the pharmaceutical manufacturing, research and development and the pharmaceutical business segments of Fosun Pharma, and the gain from the transfer of 9.56% equity interest in Shanghai Forte Land Co., Ltd., which will be recognised in the results of Fosun Pharma for the six months ended 30 June 2010.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

Shanghai, the PRC, 29 July 2010

As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Fan Wei, Mr. Ding Guoqi, Mr. Qin Xuetao and Mr. Wu Ping; the non-executive director is Mr. Liu Benren; and the independent non-executive directors are Dr. Chen Kaixian, Mr. Zhang Shengman and Mr. Andrew Y. Yan.